This research demonstrates improved dual relaxivity properties in MRI contrast agents, indicating better imaging safety and effectiveness in biomedical applications.
The formulation of magnetic resonance imaging (MRI) contrast agents (CAs) that are both biologically safe and effective continues to be a significant focus and a challenge in biomedical research. This study aims to address the limitations inherent in commercially available MRI CAs by introducing a bimetallic (Gd)-Fe-metal-organic framework prepared through a streamlined, one-step solvothermal approach, thereby eliminating the need for complex postsynthetic modifications. Through the meticulous optimization of parameters, exceptionally high crystallinity was achieved in a bimetallic MOF, ensuring structural stability and enhanced performance. Notably, the integration of gadolinium (Gd) into a monometallic Fe-MOF induced a magnetic transition, shifting from ferromagnetism to paramagnetism, which unlocks inherent dual T1-T2 contrast properties without requiring external magnetic nanomaterials. This intrinsic dual relaxivity provides a self-sustained MRI signal, distinguishing it from conventional CAs. The material exhibits impressive relaxivity values: its r1 was found to be 6.03 mM-1 s-1 in agar media and 3.85 mM-1 s-1 in water media; the corresponding r2 values were 53.65 mM-1 s-1 in agar media and 26.72 mM-1 s-1 in water media. Moreover, (Gd)-Fe-MOF exhibits superior biocompatibility, with an 88.3% cell viability in MTT assays conducted on the Y79 cell line, significantly outperforming the clinically used Gd-DTPA. This work focuses on the development of an improved MRI CA that offers enhanced safety, optimized crystalline structure, and intrinsic multimodal imaging capabilities, making a significant advancement in MRI diagnostics.
No takes yet. Share an insight, caveat, or question.
Hadwani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: